Vimarsana
Biggest News Aggregation in the World

Page 13 - Arnaud Delepine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Arnaud Delepine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Arnaud Delepine Today - Breaking & Trending Today

Sanofi : to help manufacture Moderna COVID-19 vaccine, supporting global supply demands - Vimarsana News

Sanofi : to help manufacture Moderna COVID-19 vaccine, supporting global supply demands

Message : Required fields BRIDGEWATER, N.J., April 26, 2021 /PRNewswire/ -- Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna´s COVID-19 vaccine, supporting the COVID-19 pandemic and vaccine supply needs. Sanofi will leverage its established infrastructure and manufacturing expertise at its site in Ridgefield, NJ, to perform fill and finish of up to 200 million doses of Moderna's COVID-19 vaccine, starting in September 2021. "Since the beginning of the pandemic, we have been mobilizing on multiple fronts and we showed solidarity across the i...

Sanofi: New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years - Vimarsana News

Sanofi: New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

Sanofi: New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years as young as 6 years Nearly 30 data presentations at AAD and ESPD across clinical and real-world settings, including the impact of Dupixent on disease measures in uncontrolled moderate-to-severe atopic dermatitis Late-breaking Phase 2 data for rilzabrutinib, an investigational therapy for pemphigus vulgaris, a rare, debilitating autoimmune disease, to be presented at AAD PARIS - April 23, 2021 - New analyses from Dupixent (dupilumab) trials evaluat...

European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple ... - Vimarsana News

European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple ... SanofiApril 19, 2021 GMT European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma Approval based on Phase 3 IKEMA study demonstrating Sarclisa added to standard of care carfilzomib and dexamethasone reduced risk of disease progression or death by 47% in patients who had relapsed after one to three prior therapies Sarclisa combination therapy was associat...

Source: apnews.com
European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma - Vimarsana News

European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma

d the risk of progression or death by nearly half formed the basis for this important EC approval. " Sarclisa Efficacy and Safety Profile in Difficult-to-Treat Patients This approval is based on data from the Phase 3 IKEMA study, a randomized, multi-center, open label clinical trial that enrolled 302 patients with relapsed MM across 69 centers spanning 16 countries. The primary endpoint of IKEMA was progression free survival (PFS). While median PFS, defined as time to disease progression or death, for Kd was 19.15 months, the median PFS for patients receiving Sarclisa added to carfilzomib a...

Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities - Vimarsana News

Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities

Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities Sanofi will invest €400 million over five years to create a unique vaccine